Syros stock rises as tamibaroten gets FDA fast-track status for rare blood cancer

FDA written on wooden cube with keyboard, calculator, graph, glasses.  Business concept

Irina Drozd

The US Food and Drug Administration (FDA) has granted fast track designation to Syros Pharmaceuticals’ (NASDAQ: SYRS) tamibaroten for the treatment of high-risk myelodysplastic syndrome (HR-MDS).

MDS is a group of cancers in which immature blood cells occur in the bone marrow

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *